Genovis Ab

Hansa Medical Ab

Maria Allhorn

Mattias Collin

Falk Nimmerjahn

Rolf Lood

Jonathan Sjögren

Karl Carlstrom

Anders Olin

Kutty Selva Nandakumar

Karl CARLSTRÖM

The invention provides an EndoS polypeptide, or a polynucleotide encoding an EndoS polypeptide, for use in a method for treating or preventing a disease or condition mediated by IgE antibodies.

Treatment for IgE-mediated disease

The invention provides an endoglycosidase, referred to as EndoS49 and having the amino acid sequence of SEQ ID NO: 1. EndoS49 was isolated fromstrain NZ131 and is a homolog of EndoS. EndoS49 has specific endoglycosidase activity on native IgG and cleaves a larger variety of Fc glycans than EndoS. A mutant thereof where the glutamic acid at position 186 of SEQ ID NO: 1 was substituted was produced: said mutant lacks endoglycosidase activity but is capable of binding to IgG. Methods using EndoS49, deletions thereof and said mutant, especially for assessing glycosylation of IgG or for isolating IgG are disclosed.

[object Object]

The inventions provides methods and kits for the dissociation of Fc&#x3b3;-receptor-IgG complexes, and methods and kits for the isolation of IgG and Fc and Fab fragments of IgG.

Method of assessing glycosylation state or functional quality of an IgG containing sample

Growing community of inventors

Ramlosa, Sweden

Maria Allhorn